Assessment and Management of Prepubertal Gonadotropin Levels
Clinical Evaluation and Referral
- Baseline LH, FSH, and estradiol should be assessed at age 13 years in prepubertal survivors of cancer or those at risk of delayed puberty, as recommended by the American Society of Clinical Oncology 1
- Prepubertal females age ≥11 years with failure to initiate or progress through puberty require laboratory evaluation, according to the American Society of Clinical Oncology 2
- FSH and estradiol measurement is recommended for prepubertal females with signs suggestive of premature ovarian insufficiency, as suggested by the American Society of Clinical Oncology 2
- Refer to pediatric endocrinology when prepubertal females have no signs of puberty by age 13 years with elevated FSH levels at laboratory screening, as recommended by the American Society of Clinical Oncology 2
Diagnostic Thresholds
- An FSH cut-off ≥10 IU/L at age 10 years or older indicates ovarian impairment requiring pubertal induction in conditions like Turner syndrome, according to the European Hematology Association 4
- Elevated FSH levels (>35 IU/L) with LH >11 IU/L indicate hypergonadotropic hypogonadism, as defined by the European Neurological Society 5